SARS-CoV-2 RBD of Spike protein, L452R, T478K – lineage B.1.617.2 – Indian Delta Variant

Reference:
Product nameSARS-CoV-2 RBD of Spike protein, L452R, T478K – lineage B.1.617.2 – Indian Delta Variant
Origin speciesSARS-COV2
Expression systemEukaryotic expression
BufferPBS, pH7.5
Delivery conditionDry Ice
Storage condition4°C for short term; -20°c or -80°C for long term
BrandProteoGenix
Host speciesMammalian cells
Fragment TypeSpike protein fragment
Aliases /SynonymsB.1.617.2, VOC21APR-02, G/452R.V3, Indian variant, Delta variant
ReferencePX-COV-P061
NoteFor research use only. Not suitable for in vitro diagnostic and human use.

General information on SARS-CoV-2 RBD of Spike protein, L452R, T478K – lineage B.1.617.2 – Indian Delta Variant protein

There are currently three circulating clades of lineage B.1.617 – B.1.617.1, B.1.617.2, and B.1.617.3, shown in chronological order of detection. Although these clades display different mutation profiles, all were initially detected in India and have since spread to other continents. Of the three clades, lineage B.1.617.2 carrying receptor-binding domain mutations L452R and T478K is the one causing more concern among the scientific community and governments.
Public Health England (PHE) has recently escalated lineage B.1.617.2 from variant under investigation (VUI) to variant of concern – VOC21APR-02 – due to the steep increase of cases in the UK. In early May 2021, the number of cases of this variant with a travel history in India already represented a minority of the total amount of B.1617.2 cases detected in the country. Data suggests a sustained spread of the new variant and hints to its higher infectivity in comparison to other circulating variants of SARS-CoV-2. Although the absolute number of cases remains low, the spread rate of this variant is very high. These findings suggest variant B.1.617.2 may possess transmissibility similar to that of B.1.1.7, one of the most abundant variants of the virus circulating in the UK since September 2020. But it is still unclear if this variant will outcompete the UK strain.
Mutation L452R has been previously detected in two other high abundance variants circulating in the US (lineages B.1.427 and B.1.429). This mutation has been associated with weaker neutralization of the virus by convalescent plasma. However, the available data is still insufficient to understand how this amino acid change might affect vaccine efficiency. Less data is available on the effects of mutation T478K. This amino acid change occurs in the region of interaction between the virus and the human ACE2 receptor. Several lineages of SARS-CoV-2 have been shown to carry this mutation, namely lineage B.1.1.519 (US/Mexico lineage). Moreover, several reports indicate that its abundance among circulating variants has shown a marked increase since January 2021. To date, there are no reports regarding the effects of this change on the transmissibility and immune evasion ability of SARS-CoV-2. For this reason, more functional studies are necessary to determine the potential effect of these combined RBD mutations on COVID-19 vaccine and drug efficiency.

Reviews

There are no reviews yet.

REVIEW YOUR PRODUCT

Be the first to review “SARS-CoV-2 RBD of Spike protein, L452R, T478K – lineage B.1.617.2 – Indian Delta Variant”

Your email address will not be published. Required fields are marked *

Related products

Stable Istotope Labelled Bamlanivimab Biosimilar – Anti-Covid Spike RBD mAb – Research Grade
Biosimilar Stable Istotope Labelled Bamlanivimab Biosimilar – Anti-Covid Spike RBD mAb – Research Grade PX-TA1031-SIL 1500€
Stable Istotope Labelled Tixagevimab Biosimilar – Anti-Covid Spike RBD mAb – Research Grade
Biosimilar Stable Istotope Labelled Tixagevimab Biosimilar – Anti-Covid Spike RBD mAb – Research Grade PX-TA1032-SIL 1500€
Stable Istotope Labelled Cilgavimab Biosimilar – Anti-Covid Spike RBD mAb – Research Grade
Biosimilar Stable Istotope Labelled Cilgavimab Biosimilar – Anti-Covid Spike RBD mAb – Research Grade PX-TA1033-SIL 1500€
Stable Isotope Labeled Sotrovimab  Biosimilar – Anti-Spike glycoprotein mAb – Research Grade
Biosimilar Stable Isotope Labeled Sotrovimab Biosimilar – Anti-Spike glycoprotein mAb – Research Grade PX-TA1637-SIL 1500€
Bebtelovimab Biosimilar – Anti-SARS-CoV-2 Spike Protein mAb – Research Grade
Biosimilar Bebtelovimab Biosimilar – Anti-SARS-CoV-2 Spike Protein mAb – Research Grade PX-TA1750 400€
Beludavimab Biosimilar – Anti-Spike RBD mAb – Research Grade
Biosimilar Beludavimab Biosimilar – Anti-Spike RBD mAb – Research Grade PX-TA1797 400€
Upanovimab Biosimilar – Anti-Spike RBD mAb – Research Grade
Biosimilar Upanovimab Biosimilar – Anti-Spike RBD mAb – Research Grade PX-TA1798 400€
Amubarvimab Biosimilar – Anti-Spike RBD mAb – Research Grade
Biosimilar Amubarvimab Biosimilar – Anti-Spike RBD mAb – Research Grade PX-TA1799 400€
Romlusevimab Biosimilar – Anti-Spike RBD mAb – Research Grade
Biosimilar Romlusevimab Biosimilar – Anti-Spike RBD mAb – Research Grade PX-TA1800 400€
Anti-RBD-4 antibody (Casirivimab)
Biosimilar Anti-RBD-4 antibody (Casirivimab) PTXCOV-A552 300€
Anti-RBD-5 antibody (Imdevimab)
Biosimilar Anti-RBD-5 antibody (Imdevimab) PTXCOV-A553 300€
Stable Isotope Labeled Anti-RBD-4 antibody (Casirivimab)
SIL Stable Isotope Labeled Anti-RBD-4 antibody (Casirivimab) PTXCOV-A552-SIL 1500€
Anti-2019-nCoV(S1) – 2 (H4) antibody
Monoclonal Antibody Anti-2019-nCoV(S1) – 2 (H4) antibody PTXCOV-A514 300€
Anti-2019-nCoV(S1)-1 IgM antibody
Monoclonal Antibody Anti-2019-nCoV(S1)-1 IgM antibody PTXCOV-A542 380€
ACE2 protein – Soluble ectodomain of human ACE-2 (aa 1-740)
Receptor ACE2 protein – Soluble ectodomain of human ACE-2 (aa 1-740) PX-COV-P048 230€

Contact us

Got a question or need a quote?
Message us and we’ll get back to you 48 hours or less.